Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years - 21/06/16
, Jorien Maria Kerstjens, MD, PhD c, Saskia Spillekom-van Koulil, MSc, PhD b, Catharina Joanna Maria van der Vleuten, MD, PhD aAbstract |
Background |
Long-term adverse effects of propranolol treatment for infantile hemangioma (IH) in young children have been suggested.
Objective |
To compare growth and development in children treated with propranolol for IH with nontreated healthy controls.
Methods |
Eighty two (73%) children with IH aged 43 to 51 months treated with propranolol for 6 months or longer, and without other developmental risk factors, were recruited (cases) and matched with 4 twin counterparts and 78 children from a community-based cohort (control subjects). Parents completed the 48-months Ages and Stages Questionnaire (ASQ). Percentages of children with abnormal ASQ results were compared using χ2 analyses. Mean ASQ scores and growth were compared using Mann-Whitney U tests.
Results |
Six (7.3%) cases had abnormal ASQ results, compared with 10 (12.2%) controls (P = .292). Mean ASQ total score (25th-75th percentile) was 52.9 (50.8-57.0) for cases and 51.9 (49.0-56.0) for controls (P = .383). Height and weight of cases and controls were comparable.
Limitations |
A parent-completed screening instrument was used. The exclusion of children born at gestational age less than 36 weeks and/or children born small for gestational age partly limits generalizability.
Conclusion |
We found no increased developmental risk or growth impairment at age 4 years in patients with IH treated with propranolol.
Le texte complet de cet article est disponible en PDF.Key words : adverse effects, Ages and Stages Questionnaire, development, growth, infantile hemangioma, propranolol
Abbreviations used : ASQ, IH, LOLLIPOP
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 75 - N° 1
P. 59 - juillet 2016 Retour au numéro
Article précédent
- Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study
- Stephen Chu-Sung Hu, Feng-Lin Yen, Tsu-Nai Wang, Yu-Chih Lin, Chi-Ling Lin, Gwo-Shing Chen
- Prognosis and response to laser treatment of early-onset hypertrophic port-wine stains (PWS)
- Thierry Passeron, Aicha Salhi, Jean-Michel Mazer, Céline Lavogiez, Juliette Mazereeuw-Hautier, Chrystèle Galliot, Anne-Marie Collet-Villette, Christine Labreze, Laurence Boon, Jean-Philippe Hardy, Virginie Fayard, Cristina Bulai Livideanu, Gérard Toubel, Gabriela Georgescou, Nathalie Gral, Aude Maza, Jean-Philippe Lacour
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?